IN THE CLAIMS

Cancel Claims 2, 3, and 6-13.

Amend Claim 4 as follows:

Claim 4, line 1, change "3" to --1--.

Please add the following new claims:

--14. An oral dosage form comprising a coated capsule containing as an active principle an omega-3 polyunsaturated acid in free acid form or a pharmaceutically acceptable salt thereof, characterized in that the coating of the capsule is of a material which dissolves in a time but not pH dependent manner and is resistant to the release of the omega-3 polyunsaturated acid for a period of 30 to 60 minutes at pH 5.5 such that said omega-3 polyunsaturated acid is released in the small intestine.

--15. An oral dosage form as claimed in Claim 14, wherein said acid is eicosapenta-5,8,11,14,17-enoic acid, docosahexa-4,7,10,13,16,19-enoic acid or a mixture thereof.

--16. An oral dosage form a claimed in Claim 14, wherein said acid is present as the sole active principle.

--17. An oral dosage form as claimed in Claim 14, wherein said active principle is an omega-3 polyunsaturated acid in free acid form or a pharmaceutically acceptable salt thereof except for a lithium salt thereof.

--18. An oral dosage form as claimed in Claim 14, wherein the coating comprises iron oxide, titanium dioxide, and talc.

--19. An oral dosage form as claimed in Claim 14, wherein the capsule is a hard or soft gelatin capsule.

7 ~~--20.~~ An oral dosage form as claimed in Claim ~~15~~ 2, wherein the eicosapenta-5,8,11,14,17-enoic acid, docosahexa-4,7,10,13,16,19-enoic acid or mixture thereof is present in an oil constituent in a percentage of at least 60% w/w.

8 ~~--21.~~ An oral dosage form as claimed in Claim ~~14~~ 1 containing as an active principle a unit dose of 250 to 1,000 mg omega-3 polyunsaturated acid.

9 ~~--22.~~ A method of treating inflammatory bowel disease or reducing clinical relapse thereof, which comprises administering to a patient an effective amount of an oral dosage form comprising a coated capsule containing as an active principle an omega-3 polyunsaturated acid in free acid form or a pharmaceutically acceptable salt thereof, characterized in that the coating of the capsule is of a material which dissolves in a time but not pH dependent manner and is resistant to the release of the omega-3 polyunsaturated acid for a period of 30 to 60 minutes at pH 5.5 such that said omega-3 polyunsaturated acid is released in the small intestine.

10 ~~--23.~~ A method as claimed in Claim ~~22~~ 9, wherein the inflammatory bowel disease is Crohn's disease.

11 ~~--24.~~ A method as claimed in Claim ~~23~~ 10, wherein patients are in clinical remission for less than 24 months prior to treatment.

12 ~~--25.~~ A method as claimed in Claim ~~22~~ 9 which comprises administering a daily dosage of 20 to 50 mg/kg omega-3 polyunsaturated acid.

13 ~~--26.~~ A method of treating inflammatory bowel disease or reducing clinical relapse thereof, which comprises administering to

21